VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus.